No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BFRI Biofrontera
- 1.6600
- -0.0300-1.78%
Trading Apr 26 12:27 ET
8.45MMarket Cap-127P/E (TTM)
1.7300High1.6000Low11.76KVolume1.6600Open1.6900Pre Close19.90KTurnover0.59%Turnover RatioLossP/E (Static)5.09MShares13.420052wk High1.76P/B3.32MFloat Cap0.610052wk Low--Dividend TTM2.00MShs Float292.6000Historical High--Div YieldTTM7.69%Amplitude0.6100Historical Low1.6910Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Monday's After-Market Session
GainersKineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stoc
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announce
Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript
Analysts' Top Healthcare Picks: Biofrontera (BFRI), Alpine Immune Sciences (ALPN)
Q4 2023 Biofrontera Inc Earnings Call
Earnings Call: Biofrontera Posts Record Revenue and Outlines Growth Plans
Comments
$Biofrontera(BFRI.US$ Biofrontera posts record revenue and outlines growth plans
Update
$Biofrontera(BFRI.US$ Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Accesswire·
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules
Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth
Accesswire·
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules
Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth
1
1
7
$Biofrontera(BFRI.US$ And another! hehehe! hope my rope holds🦘
4
News
$Biofrontera(BFRI.US$ Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG 3 MINUTES AGO, 8:10 AM EST VIA ACCESSWIRE BFRI SHARE Ameluz ® transfer price to Biofrontera AG reduced significantly Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg